LY4257496 for GRPR-positive advanced breast, colorectal, prostate, and endometrial cancer (OMNIRAY)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label Phase 1, two-part interventional study that uses GRPR-targeted imaging (LY4257529) to identify eligible tumors and then treats participants with LY4257496 alone or combined with relevant standard-of-care anticancer therapies. The trial focuses on safety, tolerability, and early signs of anti-tumor activity in adults with locally advanced, unresectable, or metastatic GRPR-positive disease across several tumor types. Participants must have measurable disease by RECIST v1.1 (or documented active bone metastases) and will be followed for up to 36 weeks or until disease progression. Dose and combination regimens are guided by investigator determination within the protocol's Phase 1 framework.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.
* Must be assessed by computed tomography (CT)/magnetic resonance imaging (MRI) to confirm at least 1 of the following:

  * At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  * If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to represent active metastases
* Must have GRPR-positive disease, defined by investigator assessment of GRPR imaging.
* Must have the following histologically or cytologically confirmed diagnosis:

  * Estrogen receptor (ER+)/human epidermal growth factor receptor 2 (HER2-) breast cancer
  * ER+/HER2+ breast cancer
  * Esophageal squamous cell carcinoma
  * Adenocarcinoma of the stomach, gastroesophageal junction, or esophagus
  * Colorectal carcinoma
  * Metastatic castration-resistant prostate cancer
  * Endometrial carcinoma. Carcinosarcoma is eligible. Uterine leiomyosarcoma, adenosarcoma, or endometrial stromal sarcoma is not eligible.
  * Low-grade papillary serous ovarian cancer
  * Other non-Central Nervous System (CNS) primary GRPR-positive solid tumors (Cohorts A1 dose escalation and D1 dose expansion only)
* For participants with breast cancer diagnosis, where possible, ER and HER2 status should be assessed from the most recent tissue biopsy taken at the time of presentation with recurrent or metastatic disease.

  * To fulfill the requirement for ER+ disease by local testing, a tumor must express the ER immunohistochemistry, as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
  * HER2 status should be determined by local testing, as defined in the relevant ASCO/CAP Guidelines.
* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1.
* Must be able to comply with outpatient treatment, laboratory monitoring, imaging, and required clinic visits for the duration of trial participation.

Exclusion Criteria:

* Phase 1a (Cohort A1 and A2) only: Previously received radiopharmaceutical or radioligand therapy. For participants with prostate cancer, prior ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) is permitted.
* Has a history of ongoing acute pancreatitis within 1 year of screening.
* Previously received any prior hemi-body or whole-body radiotherapy, or prior external beam radiation therapy (EBRT) to greater than 25% of the bone marrow.
* A bone superscan, defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity.
* Has evidence of ongoing and untreated urinary tract obstruction or unmanageable urinary incontinence.
* Have known active hepatitis B virus (HBV). Exception: Individuals with chronic HBV if they:

  * Have positive HBsAg
  * Are on suppressive antiviral therapy, as allowed per local regulations prior to C1D1
  * Remain on the same antiviral treatment throughout study, and should follow local standards for continuation of therapy after completion of trial therapy.
  * Have undetectable HBV DNA ≤14 days of C1D1.
* Have known active hepatitis C virus (HCV). Exception: Individuals previously treated for HCV if they:

  * Completed curative antiviral therapy.
  * Have an HCV viral load below the limit of quantification ≤14 days of C1D1 and.
  * Are positive for anti-HCV antibodies and negative for HCV ribonucleic acid (RNA) before randomization.
* Have untreated human immunodeficiency virus (HIV) infection. Exception: Individuals who have well-controlled HIV infection/disease and they:

  * Are on a stable and permitted antiretroviral therapy (ART) regimen without changes in drug or dose, for at least 4 weeks prior to C1D1
  * Have a viral load of \<400 copies/mL ≤14 days of C1D1.
  * Have a CD4+ T-cell count ≥350 cells/mL ≤14 days of C1D1.
  * Have not had an opportunistic infection within the past 12 months.
* Has an active second malignancy unless in remission with life expectancy greater than 2 years.
* Has known hypersensitivity to any component or excipient of LY4257496.

Where it's running

• City of Hope
  Duarte, California, United States Recruiting
• University of California, Los Angeles (UCLA)
  Santa Monica, California, United States Recruiting
• Stanford University Medical Center
  Stanford, California, United States Recruiting
• Moffitt
  Tampa, Florida, United States Recruiting
• Emory University School of Medicine - Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting
• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LY4337713 for people with FAP-positive ovarian, breast, pancreatic, colorectal, or esophageal cancers

  This trial tests LY4337713, a FAP-targeted lutetium-177 therapy, in people with advanced cancers that show high levels of fibroblast activation protein (FAP).

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Newport Beach, California and 29 other locations · NCT07213791

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• High-sensitivity blood test to detect and monitor multiple cancers

  This study will test a high-sensitivity blood test that looks for tumor DNA to detect and follow several common cancers in adults with those cancers or people having routine health screenings.

  Recruiting Yonsei University · Seoul · NCT07035587

• Evaluating HTL0039732 for Advanced Solid Tumours

  This study is testing a new drug called HTL0039732, alone and with another treatment, to see if it can help people with advanced solid tumors by boosting their immune response against cancer.

  Recruiting at 6 sites Phase 1/2 Cancer Research UK · Cambridge and 5 other locations · NCT05944237

• Proximal versus total gastrectomy for locally advanced Siewert type II–III gastroesophageal junction cancer

  This will see if keeping part of the stomach (proximal gastrectomy) or removing the whole stomach (total gastrectomy) leads to better 3-year disease-free survival for adults with locally advanced Siewert type II–III gastroesophageal junction cancer.

  Recruiting Bakirkoy Dr. Sadi Konuk Research and Training Hospital · Istanbul, Istanbul · NCT07482566

• Tersolisib plus standard anti-cancer medicines for advanced HR+/HER2- breast cancer with a PIK3CA change

  This trial tests whether adding tersolisib to standard first-line anti-cancer medicines helps people with advanced hormone receptor–positive, HER2‑negative breast cancer that has a PIK3CA mutation.

  Recruiting at 179 sites Phase 3 Eli Lilly and Company · Anchorage, Alaska and 363 other locations · NCT07174336

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.